Abstract
Background
Registries are considered valuable data sources for identification of pediatric conditions treated with growth hormone (GH), and their follow-up. Currently, there is no systematic literature review on the scope and characteristics of pediatric GH registries. Therefore, the purpose of this systematic review is to identify worldwide registries reported on pediatric GH treatment and to provide a summary of their main characteristics.
Content
Pediatric GH registries were identified through a systematic literature review. The search was performed on all related literature published up to January 30th, 2021. Basic information on pediatric GH registries, their type and scope, purpose, sources of data, target conditions, reported outcomes, and important variables were analyzed and presented.
Summary
Twenty two articles, reporting on 20 pediatric GH registries, were included in this review. Industrial funding was the most common funding source. The main target conditions included in the pediatric GH registries were: growth hormone deficiency, Turner syndrome, Prader Willi syndrome, small for gestational age, idiopathic short stature, and chronic renal insufficiency. The main objectives in establishing and running pediatric GH registries were assessing the safety and effectiveness of the treatment, describing the epidemiological aspects of target growth conditions and populations, serving public health surveillance, predicting and measuring treatment outcomes, exploring new and useful aspects of GH treatment, and improving the quality of patient care.
Outlook
This systematic review provides a global perspective on pediatric GH registries which can be used as a basis for the design and development of new GH registry systems at both national and international levels.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Not applicable.
-
Ethical approval: The local Institutional Review Board deemed the study exempt from review.
References
1. Rogol, AD, Hayden, GF. Etiologies and early diagnosis of short stature and growth failure in children and adolescents. J Pediatr 2014;164:S1–14. e6. https://doi.org/10.1016/j.jpeds.2014.02.027.Search in Google Scholar PubMed
2. Collett-Solberg, PF, Jorge, AA, Boguszewski, MC, Miller, BS, Choong, CSY, Cohen, P, et al.. Growth hormone therapy in children; research and practice–a review. Growth Hormone IGF Res 2019;44:20–32. https://doi.org/10.1016/j.ghir.2018.12.004.Search in Google Scholar PubMed
3. Ayyar, VS. History of growth hormone therapy. Indian J Endocrinol Metabol 2011;15(3 Suppl):S162. https://doi.org/10.4103/2230-8210.84852.Search in Google Scholar PubMed PubMed Central
4. Kaplan, S, Underwood, L, August, G, Bell, J, Blethen, S, Brown, D, et al.. Clinical studies with recombinant-DNA-derived methionyl-human growth hormone in growth hormone-deficient children. In: Human growth hormone. Boston, MA: Springer; 1986:267–77 pp.10.1007/978-1-4615-7201-5_22Search in Google Scholar
5. Ranke, MB, Wit, JM. Growth hormone—past, present and future. Nat Rev Endocrinol 2018;14:285–300. https://doi.org/10.1038/nrendo.2018.22.Search in Google Scholar PubMed
6. Carel, JC, Ecosse, E, Landier, F, Meguellati-Hakkas, D, Kaguelidou, F, Rey, G, et al.. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012;97:416–25. https://doi.org/10.1210/jc.2011-1995.Search in Google Scholar PubMed
7. Bryant, J, Cave, C, Mihaylova, B, Chase, D, McIntyre, L, Gerard, K, et al.. Clinical and cost effectiveness of growth hormone in children. Health Technol Assess 2001;6:1–175. https://doi.org/10.3310/hta6180.Search in Google Scholar PubMed
8. Lee, JM, Davis, MM, Clark, SJ, Hofer, TP, Kemper, AR. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med 2006;160:263–9. https://doi.org/10.1001/archpedi.160.3.263.Search in Google Scholar PubMed
9. Biller, B, Vance, M, Kleinberg, D, Cook, D, Gordon, T. Clinical and reimbursement issues in growth hormone use in adults. Am J Manag Care 2000;6(15 Suppl):S817–27.Search in Google Scholar
10. Graber, E, Reiter, EO, Rogol, AD. Human growth and growth hormone: from antiquity to the recominant age to the future. Front Endocrinol 2021;12:1–19. https://doi.org/10.3389/fendo.2021.709936.Search in Google Scholar PubMed PubMed Central
11. Arnao, MDR, Sánchez, AR, García-Rey, C, Arroyo Díez, FJ, Estrada, RC, Cuartero, BG, et al.. The DATAC study: a new growth database. Description of the epidemiology, diagnosis and therapeutic attitude in a group of Spanish children with short stature. J Pediatr Endocrinol Metab 2014;27:1201–8. https://doi.org/10.1515/jpem-2013-0394.Search in Google Scholar PubMed
12. Ranke, MB, Price, DA, Reiter, EO. Growth hormone therapy in pediatrics: 20 years of KIGS. Basel, Switzerland: Karger Medical and Scientific Publishers; 2007.10.1159/isbn.978-3-318-01447-1Search in Google Scholar
13. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097.Search in Google Scholar
14. Thomas, M, Massa, G, Craen, M, de Zegher, F, Bourguignon, J-P, Heinrichs, C, et al.. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986–2001. Eur J Endocrinol 2004;151:67–72. https://doi.org/10.1530/eje.0.1510067.Search in Google Scholar
15. Thomas, M, Beckers, D, Brachet, C, Dotremont, H, Lebrethon, M-C, Lysy, P, et al.. Adult height after growth hormone treatment at pubertal onset in short adolescents born small for gestational age: results from a Belgian registry-based study. Int J Endocrinol 2018;2018:6421243. https://doi.org/10.1155/2018/6421243.Search in Google Scholar
16. Cowell, C, Dietsch, S, Greenacre, P. Growth hormone therapy for three years: the OZGROW experience. J Paediatr Child Health 1996;32:86–93. https://doi.org/10.1111/j.1440-1754.1996.tb00901.x.Search in Google Scholar
17. Werther, GA. Growth Hormone Database OZGROW TA. Growth hormone measurements vs. auxology in treatment decisions: the Australian experience. J Pediatr 1996;128:S47–51. https://doi.org/10.1016/s0022-3476(96)70011-2.Search in Google Scholar
18. Pricci, F, Villa, M, Maccari, F, Agazio, E, Rotondi, D, Panei, P, et al.. The Italian Registry of GH Treatment: electronic Clinical Report Form (e-CRF) and web-based platform for the national database of GH prescriptions. J Endocrinol Invest 2019;42:769–77. https://doi.org/10.1007/s40618-018-0980-3.Search in Google Scholar PubMed PubMed Central
19. Chung, S, Yoo, JH, Choi, JH, Rhie, YJ, Chae, HW, Kim, JH, et al.. Design of the long-term observational cohort study with recombinant human growth hormone in Korean children: LG growth study. Ann Pediatr Endocrinol Metabol 2018;23:43–50. https://doi.org/10.6065/apem.2018.23.1.43.Search in Google Scholar PubMed PubMed Central
20. Savendahl, L, Maes, M, Albertsson-Wikland, K, Borgstrom, B, Carel, JC, Henrard, S, et al.. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012;97:E213–7. https://doi.org/10.1210/jc.2011-2882.Search in Google Scholar PubMed
21. Höybye, C, Sävendahl, L, Christesen, HT, Lee, P, Pedersen, BT, Schlumpf, M, et al.. The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®). J Clin Epidemiol 2013;5:119–27.10.2147/CLEP.S42602Search in Google Scholar PubMed PubMed Central
22. Bell, JJ, Lippe, B, Romano, AA, Cernich, JT, Swinford, RD, Moawad, D. National cooperative growth study: 25 years of growth hormone data, insights, and lessons for future registries. Pediatr Endocrinol Rev: PER 2018;16:240–55. https://doi.org/10.17458/per.vol16.2018.25yearsghdata.Search in Google Scholar PubMed
23. Blethen, SL, O’Brien, F, Reinhart, R. An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection]. Pediatr Endocrinol Rev: PER 2005;2:324–6.Search in Google Scholar
24. Coutant, R, Munoz, JB, Dumitrescu, C, Schnabel, D, Sert, C, Perrot, V, et al.. Year-one effectiveness and overall safety of NutropinAq (R) for growth hormone deficiency (GHD) and other paediatric growth disorders: completion of the international cooperative growth study (iNCGS) European Registry. Horm Res Paediatr 2018;90:429–30.Search in Google Scholar
25. Bang, P, Polak, M, Woelfle, J, Houchard, A, Grp, EIRS. Effectiveness and safety of rhIGF-1 therapy in children: the European Increlex (R) growth forum database experience. Horm Res Paediatr 2015;83:345–57. https://doi.org/10.1159/000371798.Search in Google Scholar PubMed
26. Swerdlow, AJ, Cooke, R, Albertsson-Wikland, K, Borgström, B, Butler, G, Cianfarani, S, et al.. Description of the SAGhE Cohort: a large European Study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr 2015;84:172–83. https://doi.org/10.1159/000435856.Search in Google Scholar PubMed PubMed Central
27. Child, CJ, Zimmermann, AG, Chrousos, GP, Cummings, E, Deal, CL, Hasegawa, T, et al.. Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab 2019;104:379–89. https://doi.org/10.1210/jc.2018-01189.Search in Google Scholar PubMed PubMed Central
28. Ranke, MB, Dowie, J. KIGS and KIMS as tools for evidence-based medicine. Horm Res Paediatr 1999;51(1 Suppl):83–6. https://doi.org/10.1159/000053140.Search in Google Scholar PubMed
29. Ranke, MB, Lindberg, A, Board, KI. Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review. Horm Res Paediatr 2011;75:423–32. https://doi.org/10.1159/000324117.Search in Google Scholar PubMed
30. Wilton, P. Safety of growth hormone (GH)-value of a large data base. Clin Pediatr Endocrinol 1994;3(5 Suppl):61–71. https://doi.org/10.1297/cpe.3.supple5_61.Search in Google Scholar
31. Pfäffle, R, Schwab, KO, Marginean, O, Walczak, M, Szalecki, M, Schuck, E, et al.. Design of, and first data from, PATRO children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatment. Therapeut Adv Endocrinol Metabol 2013;4:3–11. https://doi.org/10.1177/2042018813479644.Search in Google Scholar PubMed PubMed Central
32. Koledova, E, Stoyanov, G, Ovbude, L, Davies, PS. Adherence and long-term growth outcomes: results from the easypod™ connect observational study (ECOS) in paediatric patients with growth disorders. Endocr Connect 2018;7:914–23. https://doi.org/10.1530/ec-18-0172.Search in Google Scholar PubMed PubMed Central
33. Clayton, P, Chatelain, P, Tatò, L, Yoo, H, Ambler, G, Belgorosky, A, et al.. A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome. Eur J Endocrinol 2013;169:277. https://doi.org/10.1530/eje-13-0069.Search in Google Scholar
34. Avorn, J. In defense of pharmacoepidemiology—embracing the yin and yang of drug research. N Engl J Med 2007;357:2219–21. https://doi.org/10.1056/nejmp0706892.Search in Google Scholar
35. Williams, RJ, Tse, T, Harlan, WR, Zarin, DA. Registration of observational studies: is it time? Can Med Assoc J 2010;182:1638–42. https://doi.org/10.1503/cmaj.092252.Search in Google Scholar
36. Cronin, MJ. From the Division of Research Technology G. Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height. J Pediatr 1997;131:S5–7. https://doi.org/10.1016/s0022-3476(97)70002-7.Search in Google Scholar
37. Coutant, R, Bosch Muñoz, J, Dumitrescu, CP, Schnabel, D, Sert, C, Perrot, V, et al.. Effectiveness and overall safety of NutropinAq® for growth hormone deficiency and other paediatric growth hormone disorders: completion of the international cooperative growth study, NutropinAq® European Registry (iNCGS). Front Endocrinol 2021;12:592. https://doi.org/10.3389/fendo.2021.676083.Search in Google Scholar PubMed PubMed Central
38. Wyatt, D. Lessons from the national cooperative growth study. Eur J Endocrinol 2004;151(1 Suppl):S55–9. https://doi.org/10.1530/eje.0.151s055.Search in Google Scholar PubMed
39. Su, P-H, Yang, C, Chao, M-C, Chiang, C-L. Monitoring adherence rate to growth hormone therapy and growth outcomes in Taiwanese children using easypod connect: observational study. JMIR Pediatr Parent 2021;4:e14774. https://doi.org/10.2196/14774.Search in Google Scholar PubMed PubMed Central
40. Graham, S, Weinman, J, Auyeung, V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr 2018;90:221–7. https://doi.org/10.1159/000493211.Search in Google Scholar PubMed
41. Haverkamp, F, Johansson, L, Dumas, H, Langham, S, Tauber, M, Veimo, D, et al.. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Therapeut 2008;30:307–16. https://doi.org/10.1016/j.clinthera.2008.02.017.Search in Google Scholar PubMed
42. Mohseni, S, Heydari, Z, Qorbani, M, Radfar, M. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab 2018;31:13–20. https://doi.org/10.1515/jpem-2017-0157.Search in Google Scholar PubMed
43. Blaschke, TF, Osterberg, L, Vrijens, B, Urquhart, J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012;52:275–301. https://doi.org/10.1146/annurev-pharmtox-011711-113247.Search in Google Scholar PubMed
44. Arnao, MDR, Sánchez, AR, López, ID, Fernández, JR, de la Vega, JAB, Fernández, DY, et al.. Adherence and long-term outcomes of growth hormone therapy with easypod™ in pediatric subjects: Spanish ECOS study. Endocr Connect 2019;8:1240. https://doi.org/10.1530/ec-19-0325.Search in Google Scholar
45. Dahlgren, J. Easypod™ a new electronic injection device for growth hormone. Expert Rev Med Dev 2008;5:297–304. https://doi.org/10.1586/17434440.5.3.297.Search in Google Scholar
46. Ranke, M, Guilbaud, O, Lindberg, A, Cole, T, Study, KPIG. Prediction of the growth response in children with various growth disorders treated with growth hormone: analyses of data from the Kabi Pharmacia International Growth Study. Acta Paediatr 1993;82:82–8. https://doi.org/10.1111/j.1651-2227.1993.tb12936.x.Search in Google Scholar
47. Howard, SR, Butler, GE. An analysis of the clinical and cost effectiveness of growth hormone replacement therapy before and during puberty: should we increase the dose? Horm Res Paediatr 2013;79:75–82. https://doi.org/10.1159/000346687.Search in Google Scholar
48. Lee, PA, Germak, J, Gut, R, Khutoryansky, N, Ross, J. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®. Int J Pediatr Endocrinol 2011;2011:6. https://doi.org/10.1186/1687-9856-2011-6.Search in Google Scholar
49. Ranke, MB, Lindberg, A. Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database). BMC Med Inf Decis Making 2011;11:38. https://doi.org/10.1186/1472-6947-11-38.Search in Google Scholar
50. Seino, Y, Yamashita, S, Morisaki, Y, Tanaka, H, Chihara, K, Tanaka, T. Japanese growth prediction model for prepubertal children with growth hormone deficiency. J Pediatr Endocrinol Metab 2012;25:909–15. https://doi.org/10.1515/jpem-2012-0189.Search in Google Scholar
51. Loftus, J, Lindberg, A, Aydin, F, Gomez, R, Maghnie, M, Rooman, R, et al.. Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormone. J Pediatr Endocrinol Metab: JPEM 2017;30:1019–26. https://doi.org/10.1515/jpem-2017-0120.Search in Google Scholar
52. Smyczynska, J, Hilczer, M, Smyczynska, U, Stawerska, R, Tadeusiewicz, R, Lewinski, A. Neural network models – a novel tool for predicting the efficacy of growth hormone (GH) therapy in children with short stature. Neuroendocrinol Lett 2015;36:348–53.Search in Google Scholar
53. Smyczyńska, U, Smyczyńska, J, Hilczer, M, Stawerska, R, Tadeusiewicz, R, Lewiński, A. Pre-treatment growth and IGF-I deficiency as main predictors of response to growth hormone therapy in neural models. Endocr Connect 2018;7:239–49. https://doi.org/10.1530/EC-17-0277.Search in Google Scholar
54. Scherdel, P, Dunkel, L, van Dommelen, P, Goulet, O, Salaün, J-F, Brauner, R, et al.. Growth monitoring as an early detection tool: a systematic review. Lancet Diabetes Endocrinol 2016;4:447–56. https://doi.org/10.1016/s2213-8587(15)00392-7.Search in Google Scholar
55. Ranke, M. The Kabi Pharmacia International Growth Study: aetiology classification list with comments. Acta Paediatr 1991;80:87–92. https://doi.org/10.1111/j.1651-2227.1991.tb12052.x.Search in Google Scholar
56. Kampstra, NA, Zipfel, N, van der Nat, PB, Westert, GP, van der Wees, PJ, Groenewoud, AS. Health outcomes measurement and organizational readiness support quality improvement: a systematic review. BMC Health Serv Res 2018;18:1–14. https://doi.org/10.1186/s12913-018-3828-9.Search in Google Scholar
57. Swerdlow, AJ, Cooke, R, Beckers, D, Borgström, B, Butler, G, Carel, J-C, et al.. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab 2017;102:1661–72. https://doi.org/10.1210/jc.2016-2046.Search in Google Scholar
58. Savendahl, L, Cooke, R, Tidblad, A, Beckers, D, Butler, G, Cianfarani, S, et al.. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol 2020;8:683–92. https://doi.org/10.1016/s2213-8587(20)30163-7.Search in Google Scholar
59. Maghnie, M, Ranke, MB, Geffner, ME, Vlachopapadopoulou, E, Dörr, HG, Albertsson-Wikland, K, editors, et al.. Safety and effectiveness of paediatric growth hormone therapy: results from the full cohort in KIGS. Basel, Switzerland: 59th Annual Meeting of The European Society of Pediatric Endocrinology (ESPE 2021 Online); 2021:142 p.Search in Google Scholar
60. Reiter, EO, Price, DA, Wilton, P, Albertsson-Wikland, K, Ranke, MB. Effect of growth hormone (GH) treatment on the near-final height of 1,258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047–54. https://doi.org/10.1210/jc.2005-2284.Search in Google Scholar PubMed
61. Boguszewski, MC, Lindberg, A, Wollmann, HA. Three-year growth response to growth hormone treatment in very young children born small for gestational age-data from KIGS. J Clin Endocrinol Metab 2014;99:2683–8. https://doi.org/10.1210/jc.2013-4117.Search in Google Scholar PubMed
62. Bakker, NE, Lindberg, A, Heissler, J, Wollmann, HA, Camacho-Hübner, C, Hokken-Koelega, AC. Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS database. J Clin Endocrinol Metab 2017;102:1702–11. https://doi.org/10.1210/jc.2016-2962.Search in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/jpem-2022-0045).
© 2022 Walter de Gruyter GmbH, Berlin/Boston
